Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
9.76
+0.29 (3.06%)
At close: Jun 24, 2025, 4:00 PM
9.76
0.00 (0.00%)
Pre-market: Jun 25, 2025, 6:53 AM EDT
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Phathom Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $16.4, which forecasts a 68.03% increase in the stock price over the next year. The lowest target is $5 and the highest is $28.
Price Target: $16.4 (+68.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $17 | Strong Buy | Maintains | $12 → $17 | +74.18% | Jun 9, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +104.92% | Jun 9, 2025 |
Needham | Needham | Strong Buy Maintains $28 | Strong Buy | Maintains | $28 | +186.89% | Jun 6, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $10 → $5 | Hold | Maintains | $10 → $5 | -48.77% | May 2, 2025 |
Guggenheim | Guggenheim | Strong Buy Maintains $18 → $12 | Strong Buy | Maintains | $18 → $12 | +22.95% | May 2, 2025 |
Financial Forecast
Revenue This Year
163.24M
from 55.25M
Increased by 195.45%
Revenue Next Year
337.51M
from 163.24M
Increased by 106.76%
EPS This Year
-3.54
from -5.29
EPS Next Year
-0.87
from -3.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 181.3M | 400.2M | 636.9M | ||
Avg | 163.2M | 337.5M | 551.8M | ||
Low | 144.0M | 264.6M | 441.0M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 228.1% | 145.1% | 88.7% | ||
Avg | 195.4% | 106.8% | 63.5% | ||
Low | 160.6% | 62.1% | 30.7% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.06 | -0.25 | 2.31 | ||
Avg | -3.54 | -0.87 | 1.40 | ||
Low | -4.21 | -2.06 | 0.90 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.